Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Goldman, J. W.; Soria, J. C.; Wakelee, H. A.; Camidge, D. R.; Gadgeel, S. M.; Yu, H. A.; Reckamp, K. L.; Papadimitrakopoulou, V.; Perol, M.; Ou, S. H. I.; Matheny, S. L.; Despain, D.; Isaacson, J. D.; Yurasov, S.; Rolfe, L.; Sequis, L. V. |
| Abstract Title: | Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC) |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 467s |
| Language: | English |
| ACCESSION: | WOS:000404711506193 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.9045 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9045 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
